Core Viewpoint - The company reported a decline in revenue and profit for the first nine months of 2025, primarily due to industry policy impacts such as centralized procurement and price adjustments in the national medical insurance drug list [1][2]. Financial Performance - The company recorded revenue of RMB 19.891 billion and a profit attributable to shareholders of RMB 3.511 billion, representing a decrease of 12.3% and 7.1% respectively compared to the same period last year [1]. - The basic earnings per share attributable to shareholders was RMB 0.3072, down 4.1% year-on-year [1]. - The revenue from the pharmaceutical business was RMB 15.450 billion, including licensing fee income of RMB 1.540 billion, which decreased by 17.2% year-on-year [1]. - The raw material products business achieved sales revenue of RMB 3.006 billion, an increase of 10.3% compared to the previous year [1]. - The functional food and other businesses reported sales revenue of RMB 1.435 billion, up 11.2% year-on-year, mainly due to stable growth in sales of Guo Weikang [1]. Research and Development - R&D expenses increased by 7.9% to RMB 4.185 billion, accounting for 27.1% of the pharmaceutical business revenue [2]. - The company has nearly 90 products in various stages of clinical trials, with 14 submitted for market approval and over 30 key products in the registration clinical stage [2]. - The company is enhancing its internal innovation capabilities and increasing R&D investment, resulting in a rich pipeline of innovative assets [2]. - The company is actively promoting the internationalization of its R&D pipeline through licensing innovative products and strategic collaborations with multinational pharmaceutical companies [2].
石药集团(01093.HK)前三季度营收198.91亿元 纯利跌7.1%至35.11亿元